<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915200</url>
  </required_header>
  <id_info>
    <org_study_id>NIH 1R21AT004490</org_study_id>
    <secondary_id>1I01CX000264-01A2</secondary_id>
    <secondary_id>R21AT004490</secondary_id>
    <nct_id>NCT00915200</nct_id>
  </id_info>
  <brief_title>N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy</brief_title>
  <official_title>N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test if the combination of two potent antioxidant nutritional
      supplements, N-acetylcysteine and the milk thistle extract silibin, is capable of correcting
      the shedding of urine protein, the oxidative stress, and the inflammation in patients with
      type 2 diabetes mellitus and diabetic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxidative stress and GSH imbalance are major contributors to the pathogenesis of diabetic
      nephropathy. Current options for the treatment of oxidative stress in diabetic nephropathy
      are limited and only partially effective, thus interest in the development of new strategies
      is high.

      The study intends to test the hypothesis that combined oral supplementation of the
      antioxidants N-acetylcysteine (NAC) and milk thistle flavonolignan silibin (as
      silibin-phosphatidylcholine) will reduce proteinuria and urinary and systemic manifestations
      of oxidative stress and inflammation, which are characteristically observed in patients with
      type 2 diabetes mellitus and related nephropathy. We expect these effects to be achieved with
      minimal or no side effects, and with good patient tolerance.

      The trial is designed as a two-center, double-blind, placebo-controlled, randomized,
      modified-factorial dose-ranging design, five-arm pilot study in patients with Type 2 diabetes
      mellitus and advanced diabetic nephropathy with proteinuria.

      Intervention consists of three-month oral administration of NAC, silibin, and/or respective
      placebos for three months. Subjects are randomized to the following five intervention arms:
      (A) placebo; (B) NAC; (C) silibin; (D) NAC + silibin; and (E) NAC + double-dose silibin.

      The primary outcome measure is urinary excretion of albumin, a marker of glomerular injury.
      Secondary outcome measures are alpha-1 microglobulin, a marker of tubular injury, and urinary
      excretion of inflammatory cytokines and C-C chemokines, i.e. markers of renal inflammation.
      In addition, peripheral blood monocytes from the same patients are analyzed for glutathione
      (GSH) content and activity of GSH metabolizing enzymes. All outcome measures are monitored in
      relation to both treatment allocation and prevalent blood and urine levels of the active
      treatment. Safety and tolerability of this combination treatment are monitored throughout the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Albumin excretion</measure>
    <time_frame>3-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary alpha-1 microglobulin excretion</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary C-C-chemokines excretion</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral blood monocyte glutathione content</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance and safety</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <condition>Proteinuria</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N-acetylcysteine placebo + silibin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine active + silibin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>silibin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine placebo + silibin active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetycysteine + silibin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine active + silibin active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine + high-dose silibin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine active + high-dose silibin active</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>600 mg orally twice daily for three months</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>N-acetycysteine + silibin</arm_group_label>
    <arm_group_label>N-acetylcysteine + high-dose silibin</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>silibin</intervention_name>
    <description>480 mg orally twice daily for three months</description>
    <arm_group_label>silibin</arm_group_label>
    <arm_group_label>N-acetycysteine + silibin</arm_group_label>
    <other_name>silibin-phosphatidylcholine, Siliphos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high-dose silibin</intervention_name>
    <description>960 mg orally twice daily for three months</description>
    <arm_group_label>N-acetylcysteine + high-dose silibin</arm_group_label>
    <other_name>silibin-phosphatidylcholine, Siliphos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-acetylcysteine placebo</intervention_name>
    <description>excipient orally twice daily for three months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>silibin</arm_group_label>
    <other_name>NAC placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>silibin placebo</intervention_name>
    <description>excipient orally twice daily for three months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>silibin</arm_group_label>
    <arm_group_label>N-acetycysteine + silibin</arm_group_label>
    <other_name>silibin-phosphatidylcholine placebo, Siliphos placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, age 18-70 years old.

          -  Type 2 diabetes mellitus

          -  Diabetic nephropathy, as defined by:

               -  estimated GFR between 60 and 15 ml/min,

               -  presence of proteinuria.

          -  Current medical treatment with low dose aspirin

          -  Treatment of hypertension with (but not limited to) one diuretic, one beta- blocker
             and one medication from the classes ARBs or ACE inhibitors.

          -  Treatment of hyperglycemia with (but not limited to) glipizide and the medication
             class insulin.

          -  Treatment of hypercholesterolemia with (but not limited to) one medication from the
             class statins.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus.

          -  Glycosylated hemoglobin (HbA1C) &gt; 10%

          -  &gt;20% variation in estimated GFR, during last 6 months

          -  SBP &gt;170 mmHg or DBP &gt;100 mmHg on medications

          -  Other secondary forms of hypertension (endocrine, renovascular)

          -  History of intolerance to:

               -  Both ACE-I and ARBs;

               -  The investigational supplements;

               -  Iodinated radiologic contrast material.

          -  Known non diabetic renal disease, or history of solid organ transplantation.

          -  Hepatitis virus or Human Immunodeficiency virus infections

          -  Use of one of the following medications within 2 months prior to enrollment in the
             study:

               -  Metformin.

               -  Thiazolidinediones (pioglitazone or rosiglitazone);

               -  Prescription-grade vitamin E, vitamin C, systemic steroids, and/or non-steroidal
                  anti-inflammatory agents;

               -  Over-the-counter vitamin E, vitamin C, and/or non-steroidal anti-inflammatory
                  agents.

               -  Over-the-counter antioxidants supplements including: Lipoic acid, Coenzyme Q10,
                  N-acetyl-cysteine (NAC), Glutathione (GSH), Chromium, Fish-oil extracts (omega-3
                  fatty acids), Soy extracts (isoflavones), Milk thistle extract (silymarin),
                  Green-tea preparations, Pomegranate extracts, Grape extracts, and Prickly pear
                  extract.

          -  Active coronary artery disease or cerebral vascular disease within 3 months prior to
             signing the informed consent.

          -  Hepatic dysfunction as defined by abnormal total bilirubin or liver enzymes (ALT, AST)
             &gt;2 times upper limit of normal range.

          -  Active malignancy.

          -  History of drug or alcohol dependency.

          -  Psychiatric or neurological condition, preventing aware consent to the study and/or
             adherence to the study protocol

          -  Unwillingness to practice birth control throughout the study.

          -  Participation to another clinical study within 1 month prior to signing the informed
             consent form.

          -  Planned move to outside the study area, surgery or radiographic studies utilizing
             iodine-based contrast material within the next one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Fanti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Hlth Sci Ctr San Ant</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Nephropathies</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Monocytes</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Silymarin</keyword>
  <keyword>Acetylcysteine</keyword>
  <keyword>Dietary Supplements</keyword>
  <keyword>Complementary Therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Silybin</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

